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This project investigates the 3-D molecular modeling ofhyaluronan (HA), paclitaxel
as anticancer drug, glutaraldehyde as cross-linker and possible crosslinked form of
hyaluronic acid paclitaxel molecule along with various physical properties of uni-
molecule and multi-molecules. Modeling work had been done using Discovery
Studios 2.5 from Accelrys Inc. USA. The study focuses on targeted delivery of
hyaluronan crosslink paclitaxel molecule nanoparticle to cancer cells in all-purpose.
The generated model will be used in the studies ofdrug delivery to cancer cells.
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1.1 Background Of Study
Cancer causes 13% of all human deaths in 2007 plays as one of major disease
(Gul-e-Saba, et al., 2010). Cancer is a result ofuncontrolled growth, invasion and
metastatic behavior of group of cells which affects people at all ages and genders
with the risk for most type increasing with age (Pal &Nayak, 2010). Chemotherapy
cancer drugs are not specific and feared because ofa patient's apprehension about
toxic consequence. Paclitaxel is an anticancer drug that inhibits angiogenesis and
reduces proliferation oftumor cell. However its practical use is limited due to its low
solubility in water as well as other pharmaceutical solvents compatible in intravenous
administration (Al-Ghananeem, et al., 2009). Effective targeted drug delivery is vital
to interfering the cancer cells and tumor growth leaving the normal dividing cells.
Hyaluronan (HA) is a main ligand ofCD44 receptor cells and act as the major
components of extracellular matrix (ECM) (Gul-e-Saba, et al., 2010).
Overexpression ofHA-CD44 on cancer cells result in enhanced binding which will
play important role in development oftargeted control drug delivery to cancer cells
(Al-Ghananeem, et al., 2009). Structured-based computational methods boost up the
imperative targeted drug delivery with a well characterize target and desired
attributes in high speed. To overcome the problem associated with currently
available drugs, the need for drug modeling assist better understanding regarding the
interactions of the drug with microenvironment in the body at the disease sites
(Mandal, et al., 2009). Therefore, the study of hyaluronan crosslink paclitaxel
molecule nanoparticle as potential anticancer drug delivery to cancer cells will be
modeled and discussed using Discovery Studios 2.5 (Accelrys Inc., USA).
1.2 Problem Statement
When any new type ofdrugs is to be used in human body, the process ofdesign
and development of drug will involve many trial and error experiments based on
previous research. This method is time consuming, costly and fraught with
uncertainties. Computational modeling to design the molecular structure to see the
behavior ofan anticancer drug once injected in human cells isa rational approach in
drug design which is economical and saves time with limited risk offailures as far as
screening for lead compounds is concerned.
1.3 Objectives
1.3.1 To model the molecular structure of Hyaluronan crosslink Paclitaxel
molecule nanoparticles targeted drug deliver by using Discovery Studios 2.5.
1.3.2 To estimate the parameters of3-D molecular modeling structure such as bond
length, bond angle, chirality and hybridization.
1.4 Scope Of Study
In this project, the 3-D molecular structure ofHyaluronan crosslink Paclitaxel
molecule nanoparticles as potential anticancer drug targeted delivery to cancer cell
will be modeled using Discovery Studios 2.5 (Accelrys Inc., USA). Drug design
using computational modeling is one ofthe advanced tools yet that could help drug
developers and could play a key role in the pharmaceutical industry (Kumar, et al.,
2006).
1.5 Feasibility Study
Discovery Studios 2.5 (Accelrys Inc., USA) is available in Universiti Teknologi
PETRONAS computer lab for students to use atall time and together with the project
itself involves the compounds that have been known its molecular structure,
therefore computational modeling of them is possible to generate and complete
withinproject timeframe.
CHAPTER 2: LITERATURE REVIEW
2.1 The Basic of Cancer and Drug Delivery
Cancer is an intricate and life-threatening syndrome. It ishappening as an upshot
of progressive growth of chromosomal and epigenetic deviations (Kumar, et al.,
2009). There were 1,500,000 new cancer cases were estimated and approximately
560,000 deaths from cancer in 2010 (Jemal, et al., 2010).The hallmarks of cancer
cells occur from deregulation ofcell proliferation (Shi, et al., 2006). Unlike normal
cell which grow and divide and die over some time, cancer cell continues on growing
and divide out of control and do not die as shown in figure 1. Rapid growth of
abnormal cells is the most important defining feature of cancer which can attack
contiguous parts ofthe body and extents to other organs (Pal, 2003).
Figure 1:The Differences between Normal Cell and Cancer Cell Division
(http://www.chem.ucla.edu/dept/Faculty/gimzewski/nnano2.html)
Although, chemotherapeutic drugs are widely used for the treatment of cancer,
but the use of these drugs is often associated with patient toxicity and poor tumor
delivery (Rios-Doria, et al., 2012). Cancer cells are sensitive to chemotherapy at
early stage. However, it often develops assimilated confrontation upon repeated
chemotherapy sequences (Carelle, et al., 2002). The conflict originated by an
anticancer drug spreads cross-resistance to a huge range of drugs having diverse
chemical structures and cellulartargets (O'connor, 2007).
Normal cells Cancer celts
Figure 2: Normal Cells and Cancer Cells Differences(http://jenneink.blogs.com/iennethink/2007/01/cancer_pubHcat.html)
Therefore, cancer drug delivery is no longer simply wrapping the drug in new
formulations for different routes of delivery but includes the knowledge and
experiences from other technologies to provide a vast range of strategies available
for drug delivery in cancer (Jain M.D, 2005). The recent focus in development of
cancer therapies is on targeted drug delivery to provide therapeutic concentrations of
anticancer agents at the site ofaction and spare the normal tissues. To improve the
bio-distribution of cancer drugs, nanoparticles have been designed to solve several
limitations of conventional drug delivery systems for optimal size and surface
characteristics to increase their circulation time in the bloodstream (Cho, et al.,
2008).






2.2 Natural Products in Cancer Chemotherapy
Nature is an attractive source of new therapeutic candidate compounds as a
tremendous chemical diversity is found in millions of species of plants, animals,
marine organisms and microorganisms (B da Rocha, etal., 2001). When it comes to
treatment, humans have always turned to nature. The medicinal value ofplants has
been recognized by almost every society on this planet. Up to the nineteenth century,
herbal extracts containing mixtures ofnatural products provided the main source of
folk medicine (Lamari &Cordopatis, 2008). Since the 1940s, 175 anticancer drugs
have been developed and are commercially available in the United States, Europe
and Japan whereby 65% ofthese were inspired from natural products, semisynthetic
modifications of natural products, natural mimics or synthetic molecules with
pharmacophores from natural products (Newman &Cragg, 2007).
Drugsdenetoped from natural! sources.
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Figure 4: Drugs Developed from Natural Sources (B da Rocha, etal., 2001)
Plant-derived: anticancer agents. WHcrobe-derreed anticancer agents.
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; Rapamicinis also a potent irnmunosiipressanl.
Figure 5: Nature-derived Anticancer Agents (B da Rocha, et al., 2001)
The development ofnovel agents from natural sources presents obstacles that
are not usually met when one deals with synthetic compounds. Paclitaxel was
originally isolated from the bark ofthe yew tree Taxus brevifolia, a finite source of
the compound. It took some years to develop a semi-synthetic analog (docetaxel)
which is derived from a renewable source, the leaves of Taxus baccata. The taxanes
paclitaxel and docetaxel show impressive antitumor activity against breast, ovarian
and other tumor types inthe clinic (BdaRocha, et al., 2001).
Taxol presents as the undoubted star, the best-selling anticancer drug
whereby it sales reached US $1.5 billion in the year of2000 and are still growing in
these years. However, it took 20 years from its discovery in 1967 to the first real
clinical response observed with ovarian cancer in 1987. The early supply problems
were enormous which was about 4000 Pacific yew trees had to be sacrifices for their
bark to provide 360 g of Taxol for the early clinical trials, and this rose to 380000
trees for 25 kg ofTaxol needed to treat 12000 patients in the early 1990s. The natural
product, paclitaxel, has therefore provided not only an effective drug, but also the
springboard for further developments (Mann, 2002).
Figure 6: The Bark ofPacific Yew Tree (Taxus Brevifolia)
(http://www.art.com/products/p359763516-sa-i4008474/guillermo-gonzalez-pacific-yew-
tree-taxus-brevifolia-close_up-of-bark-taxus-brevifolia.htm)
The use ofchemotherapy to treat cancer began at the start of the 20 century
with attempts to narrow the universe of chemical that might affect the disease by
developing methods to screen chemicals using transplantable tumors in rodents. The
ability ofcombination chemotherapy to cure acute childhood leukemia and advance
Hodgkin's disease in the 1960s and early 1970s overcame the prevailing pessimism
about the ability ofdrugs to cure advanced cancers, facilitated the study ofadjuvant
chemotherapy, and helped foster the national cancer program. Chemotherapy has, in
fact, transitioned to the age of "targeted therapy" nowadays. (Devita Jr. & Chu,
2008). Thus, the probability of finding one 'magic bullet' drug to cure cancer seems
to be nil. Anticancer research has mainly focused on the cancer cells and the
development ofcytotoxic drugs for efficient and selective chemotherapy. Indeed, in
chemotherapy, combinations of chemical compounds are used (Lamari &
Cordopatis, 2008).
2.3 Paclitaxel (PTX) As Anti-Cancer Drug and Mechanism ofAction
Paclitaxel is an ordinary product with antitumor bustle and a white to off-white
crystalline powder with the empirical formula C47H51NO14. Paclitaxel is obtained via
a Yew tree bark from Taxus brevifolia with a molecular weight of 853.9. The
Paclitaxel chemical name is 5p, 20-Epoxy-l, 2a,4,7p,10p,13a-hexahydroxytax-l 1-en-
9-one 4,10-diacetate 2-benzoate 13-ester with (2R, 3,S)-#-benzoyl-3-phenylisoserine.
Paclitaxel is extremely lipophilic, non-solvable in water and liquefies at around 216-
217 °C (Lee, et al., 2008). Besides that, paclitaxel also to the group of cytostatic
agents and seems to be suitable due to its tight binding to various cytoskeleton cell
constituents thus, resulting in effective local retention atthe site ofdelivery (Patil &
Joshi, 2012). The combine therapy ofpaclitaxel with other anti-tumor agents have
been used for countless cancer treatments, but its poor solubility in water and
containing certain toxicity (which confines the clinically administrated dose) has
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Figure 7: Paclitaxel Skeletal Formula (Haiqing Yuan, 1998)
The cell cycle is divided into several transition periods that are called phase and
the cells pass through the Gi phase during which DNA, and microtubule organizing
centers (MTOC) are synthesized. Then, the cells enter the G2 phase whereby it is a
period for preparation for chromosome condensation and mitosis, including the
synthesis of tubulin which is the former major component of the mitotic spindle and
the latter prerequisite for the interaction of chromosomal fibers into high order
structures. Microtubules are essential in cell mitosis and in state of dynamic
equilibrium with their subunit tubulins is a major component of the mitotic spindle
(Cooper, 2003). The cell cycle stages are shown in figure 8.
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Figure 8: Cell Cycle(http://scientopia.org/blogs/scicurious/2010/05/3l/cell-cycle-p21 -depression-and-
neurogenesis-and-in-the-hippocampus/)
Microtubules constitute an active role in cell division with their dynamic
instability and role in spindle formation during mitosis makes them an interesting
target for anticancer drug development. Paclitaxel has been found to bind to
microtubules without competing with other microtubule interactive agents,
suggesting that paclitaxel binds to a different site on the tubulin. Studies has shown
that paclitaxel stabilized microtubules containing microtubule-associated proteins
(MAPs) were also found to be stable to both low temperature and to Ca2+ in the cell,
while under the same conditions, paclitaxel treated microtubules in the absence of
MAPs will depolymerize slowly (Mishra, 2011). The stabilization of microtubules











Hyaluronan (HA) is a linear polysaccharide consisting ofalternating units ofpi,
S-TV-acetylglucosaminyl and pi, 4-glucuronic acid. It is occur in the extracellular
matrices of numerous tissues and plays a foremost role in cell proliferation,
migration and adhesion throughout tissue remodeling, inflammation and tumor
invasion (Pure' &Cuff, 2001). Hyaluronan is the bio-macromolecule most directly
responsible in the mechanical support of the cell of many tissues for join health
which is the major component ofsynovial fluid and is responsible for the structural
and metabolic integrity ofarticular cartilage (Mohapatra et al, 2008). Evidence has
indicated that hyaluronan may be involved in tumor cell metastasis through the
interaction between cell receptors with hyaluronan which therefore, ithas been used
to inhibit the growth ofcancer cells (Yu, et al., 1997).
The role of hyaturortan










Figure 10: The Role ofHyaluronan (http://www.trixsyn.com/03_hyaluronan.php)
The hyaluronan undergoes constant turnover during the daily maintenance of
basement membranes whereby it degraded into small, non-biologically active
fragments which is rapidly removed through the liver. Hyaluronan acts as major
component of the extracellular matrix (ECM) that can directly regulate inflammatory
processes through its interaction with CD44, its ceil surface receptor. Furthermore, it
is also conceivable that the hyaluronan cable may serve as a temporary scaffold that
avoids the loss of (ECM) components during extreme tissue remodeling (Yung &
Chan, 2012).
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CD44 interaction with HA, its receptor at the cell surface can lead tothe targeted
drug delivery (Yadav, et al., 2010), which afterward degraded inside the cells (Luo,
et ah, 2009). CD44 is a trans membrane glycoprotein with a wide tissue distribution
and can interact with various cell surface and extracellular ligands but its principal
ligand is HA. The binding of HA to CD44 is not constitutive but is activation
dependent which must be activated before it can interact with HA. Recognition of
HA by CD44 is depending on the degree of post-translational modifications, its
phosphorylation status, sulfation pattern and ability to form multivalent aggregates










Figure 11: Schematic Representation ofHA-CD44 Molecule (Gul-e-Saba, et al.,
2010)
Naturally, hyaluronic acid is also present in cross linked form. Studies have
shown that HA cross-linking is vital to alleviate the nascent 'cumulus' matrix that
forms around the oocyte prior to ovulation which the similar contrivances are likely
to transpire at sites in inflammation (Day & de la Motte, 2005). Several methods
have been used to cross-link perform dimerization reaction of the styrylpyridinium
(SbQ) molecules encouraged by UV light finally produces cross-linked micelles
(Tao,etal.,2012).
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2.5 Introduction to Cross-linking Methods and Glutaraldehyde as Cross-
linkers
Cross-linking is the process of chemically joining two or more molecules by a
covalent bond. Cross-linking reagents contain reactive ends to specific functional
groups on proteins or other molecule. Cross-linkers are commonly used to modify
drugs in which they are selected on the basis of their chemical reactivity and
compatibility ofthe reaction with the application. Cross-linkers are chosen based on
the characteristics such as chemical specificity, water solubility and cell membrane
permeability, spontaneously reactive or photo-reactive groups, and cleavability. A
cross-link introduces a permanent relationship where there may be a need for
frequent separation in functioning (Kluger &Alagic, 2004).
Glutaraldehyde possesses inimitable physiognomies that render it one of the
supreme operative protein crosslinking reagents and can be exist in at slightest 13
different forms depending on solution conditions as shown in figure 12. It is a linear,
5-carbon dialdehyde, a vibrant, neutral to pale straw-colored, pungent oily liquid that
is solvable in all proportions in water and alcohol, as well as in organic solvents
which mostly obtainable as acidic aqueous solutions (Migneault, etal., 2004).
In fact, studies of collagen crosslinking reactions with monoaldehyde and
dialdehydes having chain lengths of two to six carbon atoms revealed that the
reactivity in this series is exploited at five carbons which specify that glutaraldehyde
is the maximum operative crosslinking agent (Bowes &Cater, 1968). Glutaraldehyde
fixation of bio prosthetic tissue alters the mechanical characteristics of the tissue
significantly. Studies showed that the effect of different cross-linking methods on
tissue properties whereby cross-linking of bovine pericardium with glutaraldehyde
resulted in an increase of the extensibility and a reduction in stress relaxation. Thus,
glutaraldehyde has marketable availability and small cost in addition to its great
reactivity and chemically steady crosslinks (Nimni, etal., 1987).
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Figure 12: Possible Structure ofGlutaraldehyde inAqueous Solution (Nimni, etal.,
1987)
Glutaraldehyde was first applied successfully for bio prosthesis in the late 60s.
Previous studies also shown that crosslinking was performed in acetic solution with
glutaraldeyhde in order to obtain different degrees of crosslinking. It was observed
that for higher crosslinking levels the chitosan membranes become stiffer but their
strength decreases for controlling its swelling rate, drug release rate and changing of
mechanicalproperties.
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Aqueous solutions of glutaraldehyde contain a mixture of free aldehyde and
mono-and dehydrated glutaraldehyde and monomeric and polymeric hemiacetals.
Glutaraldehyde appeared as the most widely studied cross-linker of chitosan which
was often used as a comparison in the study ofnovel cross-linkers and its solutions
may contain various products resulting from aldol condensation during storage and
cyclic glutaraldehyde oligomers having atrioxane structure (Silva, et al., 2004).
OH OH
HA




Figure 13: (a) Structure ofHyaluronan (b) Chemical Cross-linking ofHyaluronan
using Glutaraldehyde (Al-Ghananeem, etal., 2009)
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2.6 Drug Modeling (Structured -based Design Molecular Modeling)
Drug design is a process which involves the identification of a compound that
displays a biological profile and ends when the biological profile and chemical
synthesis ofthe new chemical entity are optimized. Drug designing isalso known as
rational drug design and it is a process of finding new modifications based on the
biological receptors and target molecules (Dineshkumar, et al., 2010)
Structure-based computational methods continue to enhance progress in the
discovery and refinement of therapeutic agents and drugs. Molecular visualization
and molecular modeling are included. The structure-based methods are becoming
increasingly important due tothe rapid growth in structural data, and the particularly
high speed with which structures can be determined as part of a focused drug-
discovery effort with a well-characterized target. A drug target is a biomolecule
which involved in signaling or metabolic pathways that are specific to a disease
process (Marrone, et al., 1997).
Hence, for developing and commercializing drugs within a reasonable amount of
time as apotential drawback ofthe extremely slow natural processes, pharmaceutical
companies have devised proactive drug discovery methods, including recent
innovation called rational drug design. In this approach, researchers build and test
small drug-like molecules based on prior knowledge about the three-dimensional (3-
D)structures of known drug molecules (Bandyopadhyay, et al., 2005).
The drug rational model or design is the development of small molecules
with desired properties for targets, biomolecules which it is well established and is
being applied extensively by the pharmaceutical industries. The development of
small molecule such as hyaluronan and paclitaxel require examination of several
aspect including bond length, bond angle, chirality and energy. Consequently, all the
parameters can be utilized to improve drugs to accomplish desirable attributes such
as minimization of toxic side effects, improve bioavailability and overcoming of
drugresistance (Mandal, et al., 2009).
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2.6.1 Molecular Modeling and Docking
A molecule is characterized by a pair (A: B), in which A represents a
collection of atoms, and B represents a collection of bonds between pairs of atoms.
Information used for kinematic and energy computations is associated with each of
the atoms and bonds. Each atom carries standard information, such as its bond
length. Three element of information are associated with each bond are the bond
length (the distance between two atom centers), the bond angle (the angle between
two consecutive bonds) and whether the bond is rotatable or not (Teodore, et al.,
2001). Figure 9 illustrated the rotatable bonds.
Figure 14: ADrug Molecule. Spheres represent atoms and bonds connecting them
are represented bysticks. Curved arrows represent the rotatable degrees of freedom
around bonds (Teodore, et al., 2001)
Molecular docking is a computer simulation procedure to predict the
conformation of a receptor-ligand complex or asa simulation process where a ligand
position is estimated in a pre-defined binding site. Speed and accuracy are key
features for obtaining a successftil result in docking simulations. In context of
docking, energy evaluations are usually carried out with the help of a scoring
function (Dias & de Azevedo Jr., 2008). A large number of up-to-date scoring
functions are based on force field which is an empirical fit to the potential energy
surface. There are many different force field models that can be used to simulate
proteins and other organic molecule as AMBER, CHARMM, MM3, MM4 and
MMFF94 (Daunay & Micaelli, 2007). This project used CHARMM (Chemistry at




The study has been divided into 2 stages for molecular modeling as follows:
3.1.1 Uni-molecular Modeling
All of the following main molecules will be modeled separately using
Discovery Studios 2.5(Accelrys Inc., USA):




The following crosslink molecule nanoparticle will be modeled using
Discovery Studios 2.5 (Accelrys Inc., USA):
i. Hyaluronan crosslink Paclitaxel molecule nanoparticle
3.2 Project Activities
3.2.1 The Project Work Flow
The project work flow was started by conducting preliminary research which
includes the literature review on every aspect of cancer, anticancer drugs,
crosslinking and cross-linker agents, targeted drug delivery to cancer cells and drug
modeling. Then, the drug modeling was design in Discovery Studio 2.5 software by
executing the first stage ofdesigning which is the uni-molecular modeling followed
by the second stage ofdesigning the multi-molecular modeling. The results retrieved
from the software must be compared with the theory after applying the molecular







{encapsulated in the core)
Figure 15: Hyaluronan Crosslink Paclitaxel Molecule Nanoparticle Skeletal View
(Dinarvand, et al., 2011)
3.3 Tools Requirement
For this project, the main tool required is the Discovery Studio 2.5 produced by
Accelrys. This program is a software suite of life science molecular design solutions
for computational chemists and biologist since the modeling help to design the
molecular structure in high speed. For all the modeling structure, basic modeling
procedure has been applied. Tools requirement as for development of the molecular
modeling is shownbelow.
3.3.1 Software
• Discovery Studios 2.5 (Accelrys Inc., USA)
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Figure 16: User interface ofDiscovery Studios 2.5 (Accelrys Inc., USA)
Discovery Studio is a built on Pipeline Pilot platform, allowing a powerful
integration with multiple software applications that will guide through template
identification, sequence alignments, homology modeling, identification and
refinement of CDR loops, as well as subsequent analysis.
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3.4 Project Timeline
Table 1: Final Year Project I ProjectTimeline
Week(s) 1 2 3 4-5 6 7 8-11 12-13 14
Selection OfProject Topic
Preliminary Research Work OnJournal, Books AndPrevious Thesis




















Table 2: Final Year Project II ProjectTimeline









Analysis ofData - , '-T I ' ' -
Progress Report Drafting andPre-presentation to Supervisor
Submission of Progress Report (hardcopy to coordinator)
Pre-SEDEX
Draft Report, Dissertation and Technical Paper (Drafting) toSupervisor inhi His
Submission ofDraft Report
Submission ofDissertation (soft bound-3 copies)
Submission of technical paper(softcopy via Tum-it-in, andhardcopy to
Coordinator)
Oral Presentation & Submission ofProject Dissertation
(Hard Bound - 3 copies)
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CHAPTER 4: RESULTS AND DISCUSSION
4.1 Molecular Modeling
The following content illustrate the molecular modeling developed by using
Discovery Studios2.5 (Accelrys Inc., USA).
4.1.1 Uni-molecular Modeling




2-D Modelling 3-D Modelling
"fci
- 1 ***
Figure 17: Molecular modeling ofPaclitaxel
The modeling of Paclitaxel has been shown in Fig. 17 and 18. The red atom
indicates oxygen atom, the black atom indicates carbon atom, theblue atom indicates
nitrogen atom and the light grey atom indicates hydrogen atom. The bond length
between each atom has also been calculated using fiinction in the software together
with itsbasic properties as shown inTable 3 and 4, respectively.
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Figure 18: Paclitaxel in 3-D Structure























C20 - C22 Single 1.4856
C22-023 2 Double 1.2535
C18-024 Single 1.4279
C22 - 025 Single 1.3553
24
025 - C26 Single 1.4265
C26 - C27 Single 1.5431
C27 - C28 Single 1.5499
C28 - C29 Single 1.5515
C29 - C30 Single 1.5437
C30-O31 Single 1.4303
031-C32 Single 1.3598
C32 - 033 2 Double 1.2549
C32-C34 Single 1.4921
C34 - C35 Single 1.5638
C35 - C36 Single 1.5613
C36 - 037 Single 1.4355
C36-C38 Single 1.5648
C38 - 039 Single 1.4367
C38 - C40 Single 1.5527
C40 - 041 Single 1.4472
041 - C34 Single 1.4539
C40 - 042 Single 1.4405
042 - C43 Single 1.4508
C43 - C44 Single 1.5679
C44 - 045 Single 1.4355
C44 - C46 Single 1.5677
C46 - C47 Single 1.5483
C47 - 048 Single 1.4317
C46 - 049 Single 1.4466




N52 - C53 Single 1.3503
C53 - 054 Double 1.2504























C21 - H22 Single 1.0950
C21 - H23 Single 1.0915
024 - H24 Single 0.9877
C26-H25 Single 1.0946
C26 - H26 Single 1.0939
C27-H27 Single 1.0934
C27 - H28 Single 1.0936
C28-H29 Single 1.0945
C28 - H30 Single 1.0948
C29-H31 Single 1.0937
C29 - H32 Single 1.0932
C30 - H33 Single 1.0939
C30 - H34 Single 1.0946
C34 - H35 Single 1.0928
C35-H36 Single 1.0938
C35 - H37 Single 1.0952
C36 - H38 Single 1.0943
037 - H39 Single 0.9845
C38 - H40 Single 1.0934
039 - H41 Single 0.9890
C40 - H42 Single 1.0959
C43 - H43 Single 1.0974
C44 - H44 Single 1.0950




048 - H49 Single 0.9893




N52 - H53 Single 0.9676
C55 - H54 Single 1.0915
C55 - H55 Single 1.0908
C55 - H56 Single 1.0905
The Paclitaxel structure shows thetotal measurement of 113 bond length with
average bond length of1.3068 A.







Average Bond Length (A)
Number of Rings
Number ofAromatic Rings










According to Table 4, the exact molecular weight ofpaclitaxel is slightly
lower than its molecular weight due to exact molecular weight is the mass of a
molecule calculated with only the most abundant isotopes present which are usually
the lightest isotopes (University of Colorado, 2011). The theoretical value of
paclitaxel according to material safety data sheet of paclitaxel is 853.92 which is
almost near to the value of molecular weight of the uni-molecular paclitaxel 3-D
structure, 853.906 retrieved from the software. Paclitaxel shows 7 rings in its
molecular structure. However 3 of them are aromatic rings with total 14 rotatable
bonds which might becontributes to itvarious isoforms.
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Figure 19: Molecular modeling ofHyaluronan (HA)
The modeling ofHyaluronan has been shown in Fig. 19. The details ofbond
length between atoms of HA and its basic properties are shown in Table 5 and 6,
respectively.
Table 5: Bond and bond length of HA
01-C2 Single 1.4010
C2-C3 Single 1.5472




















C21 -C22 Single 1.6633
C22 - 020 Single 1.5331
C21-N23 Single 1.4346
N23 - C24 Single 1.3390
C24 - 025 2 Double 1.2421
C24 - C26 Single 1.4944
01-HI Single 0.9863
C3-H2 Single 1.0968
N23 - C24 Single 1.3390
C24 - 025 2 Double 1.2421























The HA structure shows the total measurement of 47 bond length with
average bond length of 1.280556 A.











C: 0.441, H: 0.061,




Table 6 shows the basic properties of hyaluronic acid. Total number of atom
in HA molecules are 47. The molecular weight and exact molecular weight are
almost same. Antitumor drug linkage to hyaluronan might improve targeting to
cancerous cells and overcome the problem of low drug hydrosolubility due to some
specific HA receptors (CD44) are overexpressed in various malignant cell types
(Leonelli, etal., 2008). Although various water-soluble synthetic polymers have been
exploited, naturally occurring polymers with intrinsic cell specific binding capacity
such as HA molecule have tremendous potential as target-specific drug carrier
(Manju & Sreenivasan, 2011). Hyaluronan is highly non-antigenic and non-
immunogenic, owing to its high structural homology across species and poor
interaction with bloodcomponents (Amarnath, et al., 2006).
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4.1.2 Multi-molecular Modeling
4.1.2.1 Hyaluronan crosslink Paclitaxel molecule nanoparticle
The hyaluronan crosslink were drawn randomly in stick representation as
illustrated in Fig. 20. Hyaluronan acts tumor-specific targeting vehicle to interact
with CD44 receptor at tumorcellwhereas the glutaraldehyde is the cross-linker. The
crosslinking occurred by acetalization which occur between hydroxyl groups of HA
and the aldehyde group of glutaraldehyde. The hyaluronan crosslink paclitaxel
molecule nanoparticle shows the total measurement of average bond length of
1.280745667 A. Thepaclitaxel molecules are in particle representation as illustrated
in Fig. 20 andthe details of the energy of the multi-molecular modeling is shown in
Table 7.
Figure 20: Molecular modeling of Hyaluronan crosslink Paclitaxel molecule
nanoparticle
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Hyaluronan crosslink not only further increases the drug solubility but more
importantly it enhances the targeted delivery chances to reach the cancer site. CD44
is overexpressed in human cancer cells and it is cell membrane-localized receptors or
HA binding proteins thus HA can bind to the cell surface via interactions with CD44
(Luo, et al., 2009). In similar studies, cross-linked hyaluronan particles are nano-
sized and can be attractive delivery candidates for a variety of biomedical
applications. Furthermore, the biocompatibility of the HA nanoparticles, the high
affinity toward cancer cells, and the suitable physicochemical properties of the HA
nanoparticles make it as a nano-drug delivery system being capable of selectivity
inhibiting cancer cells of solid tumor and metastatic tumor (Al-Ghananeem, et al.,
2009).
Table 7: Energy value retrieved from Discovery Studio 2.5 molecular modeling of





Initial Potential Energy -61.558
Electrostatic Energy -131.097
CHARMM Energy/Force field -61.932







Van Der Waals energy
-18.879
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Molecular docking was applied in this modeling which refers to the
computational prediction ofthe least energy pose between two interacting molecules.
The docking allowed to finds the best fit by assuming the molecule to be rigid, and
the total potential energy, often referred as energy minimization of the CHARMM
potential (or force-fields). The nature ofbond is the bond length shrinkage with the
assortment of bonds due to attractive forces between electrons and nuclei will rise
with the increase in quantity of shared electrons between bonded atoms.
The bond energies and bond length depend on many factors such as electron
affinities, size ofatom involve in the bond, differences in their electronegativity and
the overall structure of the molecule for the covalentbonds. Indeed, there is a general
trend such that the bond length is reciprocal with the bond energy. The larger
molecule is generally held fixed whereas the side chain atoms of the smaller
molecule (the ligand) are free to move during the energy minimization (Sukhwani &
Herbodt,2010).
The overall energy minimization and calculation is showed inTable 6. Initial
Potential Energy, electrostatic Energy, CHARMM Energy/Force field for HA cross-
linked paclitaxel nanoparticles were negative along with negative Van Der Waals
energy might be due to lack of any solvent in modeling and crosslink nanoparticle
simulation. However, CHARMM energy usually comes negative. The energy
minimization is calculated by the permutation of the total non-bonded and bonded
molecule energy. The non-bonded energy isthe combination between van der Waals
energy and electrostatic energy. Meanwhile, the bonded energy consists of the
grouping of4 different energies which are bond energy, angle energy, torsion energy
and improper energy. For stability of molecules theenergy matters a lot. High energy
states favor the instability in molecules. A real and rational modeled molecule
structure should be in state which correspond a model near minimum potential
energy and minimum energy arrangement of the atoms corresponds tostable state of




The rational drug design of the hyaluronan crosslink paclitaxel molecule
structure using Discovery Studio 2.5 would be multidisciplinary approaches in
developing anticancer drugs. The uni-molecular and 3-D structure of hyaluronan
crosslinkpaclitaxel molecule nanoparticle targeted delivery to cancer cells had been
successfully modeled. Hyaluronan crosslink have high potential as targeted delivery
vehicle to transport the anticancer drug, paclitaxel to cancer cells besides improving
the stability, bioavailability of anticancer hydrophobic drug. Hyaluronan crosslink
paclitaxel molecule nanoparticle targeted drug deliver to cancer cells molecular
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